Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INAB
stocks logo

INAB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-1.800
-68.42%
--
--
-1.600
-64.44%
--
--
-1.400
+16.67%
Estimates Revision
The market is revising No Change the revenue expectations for IN8bio, Inc. (INAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -15.94%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-15.94%
In Past 3 Month
Wall Street analysts forecast INAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INAB is 92.00 USD with a low forecast of 36.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast INAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INAB is 92.00 USD with a low forecast of 36.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.820
sliders
Low
36.00
Averages
92.00
High
180.00
Current: 1.820
sliders
Low
36.00
Averages
92.00
High
180.00
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$8 → $6
2025-03-14
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$8 → $6
2025-03-14
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$8
2025-02-12
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$8
2025-02-12
Reiterates
Strong Buy
Reason
Jones Trading
Soumit Roy
Hold
to
Strong Buy
Upgrades
$1.2
2025-02-11
Reason
Jones Trading
Soumit Roy
Price Target
$1.2
2025-02-11
Upgrades
Hold
to
Strong Buy
Reason
JonesResearch analyst Soumit Roy upgraded IN8bio to Buy from Hold with a $1.20 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for IN8bio Inc (INAB.O) is -0.51, compared to its 5-year average forward P/E of -2.18. For a more detailed relative valuation and DCF analysis to assess IN8bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.18
Current PE
-0.51
Overvalued PE
-0.68
Undervalued PE
-3.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.24
Undervalued EV/EBITDA
-0.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.04
Undervalued PS
-0.04
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 2792.5% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

INAB News & Events

Events Timeline

(ET)
2025-10-29
08:01:56
IN8bio adds new clinical site to INB-100 Phase 1 trial expansion
select
2025-10-27 (ET)
2025-10-27
08:22:57
IN8bio unveils fresh preclinical findings for INB-619
select
2025-08-07 (ET)
2025-08-07
16:01:49
IN8bio reports Q2 EPS ($1.24), consensus ($1.80)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
08-08NASDAQ.COM
IN8bio (INAB) Q2 Loss Narrows 77%

  • Financial Performance: IN8bio reported a significantly reduced net loss in Q2 2025, with no revenue generated but a cash position of $13.2 million projected to last until June 2026, while research and development costs decreased due to strategic prioritization.

  • Clinical Progress: The company achieved promising results in its clinical trial for INB-200 in glioblastoma, showing a median progression-free survival of 16.1 months, which is more than double the standard treatment, alongside advancements in other therapies and manufacturing capabilities.

[object Object]
Preview
4.5
06-09Benzinga
US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market'

  • Market Overview: U.S. stock futures were flat following a positive close on Friday, with the S&P 500 surpassing 6,000 points, driven by strong job growth and a cooling of tensions between Elon Musk and President Trump. Investors are awaiting upcoming inflation data and the Federal Reserve's interest rate decision.

  • Sector Performance: All sectors of the S&P 500 closed positively on Friday, led by consumer discretionary, energy, and communication services, although some individual stocks like ABM Industries and DocuSign saw significant declines after disappointing earnings reports.

[object Object]
Preview
9.0
06-02Newsfilter
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

  • Clinical Trial Results: INB-200, a gamma-delta T cell therapy for glioblastoma multiforme, shows a median progression-free survival (mPFS) of 16.1 months in patients receiving multiple doses, significantly surpassing the standard-of-care mPFS of 6.9 months.

  • Safety Profile: The treatment is well-tolerated with no serious toxicities reported, and 40% of patients remain alive and progression-free for over two years, indicating promising long-term outcomes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is IN8bio Inc (INAB) stock price today?

The current price of INAB is 1.82 USD — it has increased 4 % in the last trading day.

arrow icon

What is IN8bio Inc (INAB)'s business?

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.

arrow icon

What is the price predicton of INAB Stock?

Wall Street analysts forecast INAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INAB is 92.00 USD with a low forecast of 36.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is IN8bio Inc (INAB)'s revenue for the last quarter?

IN8bio Inc revenue for the last quarter amounts to -5.66M USD, decreased -34.53 % YoY.

arrow icon

What is IN8bio Inc (INAB)'s earnings per share (EPS) for the last quarter?

IN8bio Inc. EPS for the last quarter amounts to -3122000.00 USD, decreased -60.93 % YoY.

arrow icon

What changes have occurred in the market's expectations for IN8bio Inc (INAB)'s fundamentals?

The market is revising No Change the revenue expectations for IN8bio, Inc. (INAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -15.94%.
arrow icon

How many employees does IN8bio Inc (INAB). have?

IN8bio Inc (INAB) has 18 emplpoyees as of December 05 2025.

arrow icon

What is IN8bio Inc (INAB) market cap?

Today INAB has the market capitalization of 39.68M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free